Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
69.35 EUR | +1.31% | -7.31% | -12.91% |
05-08 | COMPUGROUP MEDICAL : Warburg Research remains its Buy rating | ZD |
05-08 | Compugroup generates less revenue after one-off effect in previous year - targets confirmed | DP |
Sales 2024 * | 1.24B 1.33B 1.83B | Sales 2025 * | 1.3B 1.39B 1.91B | Capitalization | 1.45B 1.56B 2.14B |
---|---|---|---|---|---|
Net income 2024 * | 99M 106M 146M | Net income 2025 * | 115M 124M 170M | EV / Sales 2024 * | 1.67 x |
Net Debt 2024 * | 622M 669M 918M | Net Debt 2025 * | 561M 603M 828M | EV / Sales 2025 * | 1.55 x |
P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
12.8
x | Employees | - |
Yield 2024 * |
2.47% | Yield 2025 * |
2.8% | Free-Float | 46.87% |
Latest transcript on CompuGroup Medical Societas Europaea
1 day | +1.31% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Rauch
CEO | Chief Executive Officer | 52 | 19-07-31 |
Frank Gotthardt
CEO | Chief Executive Officer | 72 | 86-12-31 |
Daniel Gotthardt
BRD | Director/Board Member | - | 03-08-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 61 | 20-06-17 | |
Director/Board Member | 59 | 20-06-17 | |
Klaus Esser
BRD | Director/Board Member | - | 03-05-25 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.34% | 324B | |
+26.51% | 218B | |
+2.06% | 147B | |
+16.29% | 58.1B | |
+1.64% | 31.33B | |
+7.51% | 30.66B | |
+95.23% | 22.3B | |
+28.31% | 21.09B | |
+2.13% | 14.88B |
- Stock Market
- Equities
- COP Stock
- COP Stock